Our Services

Lung Cancer

The two main types of lung cancer are non-small cell lung cancer and small cell lung cancer. The types are based on the way the cells look under a microscope. Non-small cell lung cancer is much more common than small cell lung cancer. Tobacco smoking is the most common cause of lung cancer.

A Novel Antibody for Targeting a Highly Expressed Activating Receptor, DLL3, on Small Cell Lung Cancer (SCLC)

  • Study nickname: TAHOE
  • Advanced or Stage IV SCLC
  • Patients will receive treatment with rovalpituzuamb tesirine or topotecan (2:1 ratio)
  • Patients must have progressed on their first treatment which must have been platinum based
  • Main study doctor (Principal Investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Sabine Ucik, at 707-521-3830 or at Sabine.Ucik@stjoe.org

A Novel Antibody for Targeting a Highly Expressed Activating Receptor, DLL3, on Small Cell Lung Cancer (SCLC)

  • Study nickname: MERU
  • Extensive tumor burdern due to small cell lung cancer (SCLC)
  • Patients will receive treatment with rovalpituzuamb tesirine or a placebo (1:1 ratio)
  • Patients must have had a favorable outcome after at least 4 cycles of first-line platinum based chemotherapy
  • Main study doctor (Principal Investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Sabine Ucik, at 707-521-3830 or at Sabine.Ucik@stjoe.org

3rd generation TKI for EGFR+ Non-small Cell Lung Cancer (NSCLC) After Removal of Tumor Clinical Trial

  • Study name: ADAURA
  • Stage IB-IIIA EGFR+ NSCLC
  • Patients will receive treatment with AZD9291 (Tagrisso: 3rd generation TKI) or a placebo (1:1 ratio)
  • Patients must have completed surgery (tumor resection) prior to enrollment
  • Main study doctor (Principal Investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Tracy Foster, at 707-521-3836 or at Tracy.Foster@stjoe.org

Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination with Osimertinib in Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer​

  • Study name: G1T38
  • Stage: IV
  • Study drug: GIT38 (CDK4/6 inhibitor) with or without osimertinib
  • Target population: Patients who failed a 1st line TKI;
    • Part 1: any EGFR mutation conferring sensitivity to TKI, Progressive Disease after 2 lines of chemotherapy for metastatic disease (patients on osimertinib at study entry without showing Progressive Disease is acceptable);
    • Part 2: T790M mutation found after Progressive Disease on 1st line of TKI, not received chemotherapy for metastatic disease (adjuvant chemotherepy is okay; may not be on osimertinib);
  • Main study doctor (Principal Investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Tracy Foster, at 707-521-3836 or at Tracy.Foster@stjoe.org

An Open-label, Non-randomized, Prospective Biomarker Study to Assess Analytic Concordance Between Non-invasive Testing and Tissue Testing for EGFR T790M Mutation Detection in Patients with Non-small Cell Lung Cancer​

  • Study nickname: AZ RADIANCE
  • Stage: IV
  • Non-treatment study
  • Biomarker study; EGFR+; patients showing Progressive Disease on TKI (except osimertinib)
  • Main study doctor (Principal Investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Tracy Foster, at 707-521-3836 or at Tracy.Foster@stjoe.org

Chemotherapy With or Without Anti-ErbB3 Antibody as 2nd, 3rd, or 4th Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Clinical Trial

  • Study nickname: SHERLOC
  • Stage IIIB-IV EGFR-negative
  • Heregulin Positive
  • Patients must have undergone one or two, or three prior lines of treatment
  • Patients receive treatment with chemotherapy, with or without MM-121, an anti-ErbB3 antibody (2:1 ratio)
  • Main study doctor (Principal Investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Sabine Ucik, at 707-521-3830 or at Sabine.Ucik@stjoe.org

A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Metastatic Non-Small Cell Lung Cancer whose Tumors Have High PD-L1 Expression

  • Study nickname: CYPRESS 1
  • Stage: IV
  • EGFR-
  • Line of therapy: 1st line
  • Study drug: Pembrolizumab with or without AM0010 (interleukin 10)
  • Target population: Wild type; treatment naïve; PD-L1 high
  • Main study doctor (Principal Investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Sabine Ucik, at 707-521-3830 or at Sabine.Ucik@stjoe.org

A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1​

  • Study nickname: CYPRESS 2
  • Stage: IV
  • EGFR-
  • Line of therapy: 2nd line
  • Study drug: Nivolumab +/- AM0010 (interleukin 10)
  • Target population: Wild type; PD-L1 low; no prior anti PD1/anti PD-L1
  • Main study doctor (Principal Investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Sabine Ucik, at 707-521-3830 or at Sabine.Ucik@stjoe.org

Immunotherapy and Anti-hyaluronan Factor for Relapsed or Refractory Non-small Cell Lung Cancer (NSCLC) Clinical Trial

  • Study nickname: HALO-107-101
  • Locally advanced or Stage IV (metastatic)
  • All patients receive treatment
  • Patients must have failed at least 1 previous platinum-based chemotherapy prior to enrolling
  • Patients need to be HA-high
  • All patients are given pembrolizumab + PEGPH20
  • Study website: www.halo101.com
  • Principal Investigator: Ian Anderson, MD
  • For more information, please contact the lead coordinator, Tracy Foster, at 707-521-3836 or at Tracy.Foster@stjoe.org

A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (NSCLC)​

  • Study nickname: KEYNOTE-671
  • Stage: Resectable IIB-IIIA
  • EGFR+ or EGFR-
  • Line of therapy: Noeadjuvant/adjuvant
  • Study drug: Platinum doublet chemo with or without pembrolizumab
  • Target population: Potentially resectable (neoadjuvant) or resected (adjuvant); any PD-L1 status
  • Principal Investigator: Ian Anderson, MD
  • For more information, please contact the lead coordinator, Tracy Foster, at 707-521-3836 or at Tracy.Foster@stjoe.org